See more : Petrotx – Limited Partnership (PTX.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Absci Corporation (ABSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Absci Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Godsinlösen Nordic AB (publ) (GIAB.ST) Income Statement Analysis – Financial Results
- Zinc Media Group plc (ZIN.L) Income Statement Analysis – Financial Results
- Dewmar International BMC, Inc. (DEWM) Income Statement Analysis – Financial Results
- Dong Suh Companies Inc. (026960.KS) Income Statement Analysis – Financial Results
- AfterNext HealthTech Acquisition Corp. (AFTR-UN) Income Statement Analysis – Financial Results
Absci Corporation (ABSI)
About Absci Corporation
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 5.72M | 5.75M | 4.78M | 4.78M | 2.06M |
| Cost of Revenue | 47.57M | 13.04M | 6.65M | 11.45M | 4.31M |
| Gross Profit | -41.85M | -7.29M | -1.87M | -6.67M | -2.25M |
| Gross Profit Ratio | -731.88% | -126.85% | -39.15% | -139.50% | -109.27% |
| Research & Development | 48.07M | 58.91M | 44.59M | 11.45M | 4.31M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 37.83M | 40.55M | 28.78M | 5.50M | 3.52M |
| Other Expenses | 35.33M | 13.04M | 6.65M | 1.13M | 491.00K |
| Operating Expenses | 121.23M | 112.50M | 80.02M | 18.08M | 8.33M |
| Cost & Expenses | 121.23M | 112.50M | 80.02M | 18.08M | 8.33M |
| Interest Income | 0.00 | 972.00K | 3.43M | 634.00K | 268.00K |
| Interest Expense | 1.01M | 972.00K | 3.43M | 634.00K | 268.00K |
| Depreciation & Amortization | 14.00M | 13.04M | 6.65M | 1.13M | 491.00K |
| EBITDA | -95.46M | -91.36M | -99.77M | -12.59M | -5.83M |
| EBITDA Ratio | -1,669.41% | -1,589.63% | -2,086.43% | -263.35% | -282.77% |
| Operating Income | -115.52M | -106.75M | -75.24M | -13.30M | -6.27M |
| Operating Income Ratio | -2,020.20% | -1,857.49% | -1,573.36% | -278.26% | -304.13% |
| Total Other Income/Expenses | 5.05M | 1.39M | -34.62M | -1.05M | -319.00K |
| Income Before Tax | -110.47M | -105.37M | -109.86M | -14.35M | -6.58M |
| Income Before Tax Ratio | -1,931.90% | -1,833.39% | -2,297.34% | -300.27% | -319.61% |
| Income Tax Expense | 100.00K | -461.00K | -8.90M | 216.00K | 217.00K |
| Net Income | -110.57M | -104.90M | -100.96M | -14.57M | -6.80M |
| Net Income Ratio | -1,933.65% | -1,825.37% | -2,111.25% | -304.79% | -330.15% |
| EPS | -1.20 | -1.15 | -1.09 | -0.16 | -0.07 |
| EPS Diluted | -1.20 | -1.15 | -1.09 | -0.16 | -0.07 |
| Weighted Avg Shares Out | 92.03M | 90.85M | 92.65M | 92.25M | 92.25M |
| Weighted Avg Shares Out (Dil) | 92.03M | 90.85M | 92.65M | 92.25M | 92.25M |
Absci Announces Speaker Lineup for Inaugural R&D Day, Including Renowned Global Business Leader Sandi Peterson and VP of Applied Research at NVIDIA Jonathan Cohen
VANCOUVER, Wash. and NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the speaker lineup for its inaugural R&D Day on Wednesday, October 4th, 2023.
Absci to Host R&D Day on October 4, 2023
VANCOUVER, Wash. and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will host its first R&D Day on Wednesday, October 4th, 2023 in New York City....
Biotech company Absci lays off 30 employees, about 15% of staff
Publicly traded biotech company Absci is laying off 30 employees, or approximately 15% of its workforce.
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.
The 3 Most Undervalued Penny Stocks to Buy Now: August 2023
Penny stocks are often defined as stocks trading under $5 per share, those with a very low price per share or market capitalization, and are generally higher-risk. Now, despite many such stocks certainly carrying a relatively high risk profile, this...
Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results
Entered into partnership with Google Ventures-backed biotech company to discover innovative new medicines Entered into collaboration with Caltech, supported by the Gates Foundation, to discover affordable HIV therapeutic vaccinations VANCOUVER, Wash. and NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) --...
Absci Appoints Zach Jonasson, Ph.D., as Chief Financial Officer and Chief Business Officer
Addition of veteran biotech leader to further support Absci's next stage of growth Addition of veteran biotech leader to further support Absci's next stage of growth
Absci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development
VANCOUVER, Wash., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI ), a generative AI drug creation company, today announced that leading researchers at the California Institute of Technology (Caltech) in conjunction with Absci, a leader in AI drug...
Absci to Participate in the UBS MedTech, Tools and Genomics Summit 2023
VANCOUVER, Wash. and NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming UBS MedTech, Tools and Genomics Summit 2023 in Dana...
Beyond OpenAI: 7 promising startups that have saved lives, sped up drug development and improved manufacturing
OpenAI is stealing the spotlight as the definitive artificial-intelligence startup — for now. Backed by Microsoft Corp. MSFT, the progenitor of ChatGPT-4 has become the focus of the AI wave, but other AI startups are emerging in fields including healthcare,...
Source: https://incomestatements.info
Category: Stock Reports